![SPRAVATO® (esketamine) CIII Nasal Spray: The First and Only N-Methyl D-Aspartate (NMDA) Receptor Antagonist Approved in Conjunction With an Oral Antidepressant for the Treatment of Adults With Treatment-Resistant Depression | Psychiatrist.com SPRAVATO® (esketamine) CIII Nasal Spray: The First and Only N-Methyl D-Aspartate (NMDA) Receptor Antagonist Approved in Conjunction With an Oral Antidepressant for the Treatment of Adults With Treatment-Resistant Depression | Psychiatrist.com](https://www.psychiatrist.com/wp-content/uploads/2021/06/JA18039graphic1.gif)
SPRAVATO® (esketamine) CIII Nasal Spray: The First and Only N-Methyl D-Aspartate (NMDA) Receptor Antagonist Approved in Conjunction With an Oral Antidepressant for the Treatment of Adults With Treatment-Resistant Depression | Psychiatrist.com
![SPRAVATO®: A New Option for Treatment-Resistant Depression - PAKC - Psychiatry Associates of Kansas City SPRAVATO®: A New Option for Treatment-Resistant Depression - PAKC - Psychiatry Associates of Kansas City](https://pakconline.com/wp-content/uploads/2023/01/kansas-city-ketamine-spravato-PAKC.webp)
SPRAVATO®: A New Option for Treatment-Resistant Depression - PAKC - Psychiatry Associates of Kansas City
![These highlights do not include all the information needed to use SPRAVATO ® safely and effectively. See full prescribing information for SPRAVATO ®. SPRAVATO ® (esketamine) nasal spray, CIII Initial U.S. Approval: 1970 (ketamine) These highlights do not include all the information needed to use SPRAVATO ® safely and effectively. See full prescribing information for SPRAVATO ®. SPRAVATO ® (esketamine) nasal spray, CIII Initial U.S. Approval: 1970 (ketamine)](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=spravato-01.jpg&id=708098)
These highlights do not include all the information needed to use SPRAVATO ® safely and effectively. See full prescribing information for SPRAVATO ®. SPRAVATO ® (esketamine) nasal spray, CIII Initial U.S. Approval: 1970 (ketamine)
![Dépression résistante : SPRAVATO, nouvel antidépresseur à base d'eskétamine en solution pour pulvérisation nasale Dépression résistante : SPRAVATO, nouvel antidépresseur à base d'eskétamine en solution pour pulvérisation nasale](http://vidalactus.vidal.fr/gestionnaire/_images/mediatheque/Capturedecran2020-10-08a15.16.40.png)